SAN DIEGO, CA – July 14, 2022 — Antharis Therapeutics Inc., a biopharmaceutical company developing a leading portfolio of oncology-related immunotherapeutics, today announced the completion of their acquisition of Cassyni Biopharma. This acquisition brings a number of new, early-stage assets to Antharis’s pipeline. The deal marks Antharis’s rapid growth as a company to sit at the leading edge of biotechnology companies generating high-potential biologic assets for the treatment of cancer in multiple therapeutic classes.
“Acquiring Cassyni increases our company’s pipeline, expands Antharis Therapeutics work into new therapeutic areas to better serve future patients, and is a very exciting step forward as Antharis moves into pre-IND work this year,” said Dr. Raphael Ribeiro-Pinaud, CEO & Chairman of Antharis Therapeutics.
Antharis leverages a unique platform for the discovery, characterization, and validation of monoclonal antibody assets in the oncology space. The company’s scientific approach to developing immunotherapeutics and specialized platform have delivered, at a significantly higher rate than the industry norm,,one of the largest preclinical portfolios in the industry and supported the company’s recent successful Series A fundraising. Antharis will begin pre-IND work on a selection of their assets this year.
About Antharis Therapeutics
Antharis Therapeutics Inc. is a biopharmaceutical company involved in the discovery and development of immunotherapeutics to address devastating diseases for which there are limited or unsatisfactory treatment options. Antharis is focused on oncological (cancer) diseases, as this is one of the largest markets in need of therapies and where our team has its greatest expertise. Antharis is based in the Greater San Diego Area, California, one of the prime biotechnology hubs in the world and is led by Dr. Raphael Ribeiro-Pinaud, CEO & Chairman. For more information, visit www.antharistherapeutics.com.
